Abstract
These observations suggest several immediate clinical strategies. In gene therapy, approaches could be targeted to obtain cycling of hematopoietic stem cells and gene-carrying retrovirus vector integration followed by engraftment at an appropriate time interval which favors engraftment. The same type of approach can be utilized for stem cell expansion approaches. Alternatively marrow or peripheral stem cell engraftment can be obtained with minimal to no toxicity in allochimeric strategies in such diseases as sickle cell anemia or thalassemia. A similar approach could be useful in obtaining cell engraftment with minimal toxicity in therapies employing cellular immune (T-cell and NK-cell) attack against cancer. These areas of clinical application are outline in Table 3.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Nilsson S. K., Dooner M. S., Quesenberry P. J. Synchronized cell-cycle induction of engrafting long-term repopulating stem cells. Blood. 1997 Dec 1;90(11):4646–4650. [PubMed] [Google Scholar]
- Nilsson S. K., Dooner M. S., Tiarks C. Y., Weier H. U., Quesenberry P. J. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood. 1997 Jun 1;89(11):4013–4020. [PubMed] [Google Scholar]
- Nilsson S. K., Hulspas R., Weier H. U., Quesenberry P. J. In situ detection of individual transplanted bone marrow cells using FISH on sections of paraffin-embedded whole murine femurs. J Histochem Cytochem. 1996 Sep;44(9):1069–1074. doi: 10.1177/44.9.8773573. [DOI] [PubMed] [Google Scholar]
- Peters S. O., Kittler E. L., Ramshaw H. S., Quesenberry P. J. Ex vivo expansion of murine marrow cells with interleukin-3 (IL-3), IL-6, IL-11, and stem cell factor leads to impaired engraftment in irradiated hosts. Blood. 1996 Jan 1;87(1):30–37. [PubMed] [Google Scholar]
- Peters S. O., Kittler E. L., Ramshaw H. S., Quesenberry P. J. Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. Exp Hematol. 1995 May;23(5):461–469. [PubMed] [Google Scholar]
- Quesenberry P., Levitt L. Hematopoietic stem cells (third of three parts). N Engl J Med. 1979 Oct 18;301(16):868–872. doi: 10.1056/NEJM197910183011605. [DOI] [PubMed] [Google Scholar]
- Ramshaw H. S., Crittenden R. B., Dooner M., Peters S. O., Rao S. S., Quesenberry P. J. High levels of engraftment with a single infusion of bone marrow cells into normal unprepared mice. Biol Blood Marrow Transplant. 1995 Dec;1(2):74–80. [PubMed] [Google Scholar]
- Ramshaw H. S., Rao S. S., Crittenden R. B., Peters S. O., Weier H. U., Quesenberry P. J. Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. Blood. 1995 Aug 1;86(3):924–929. [PubMed] [Google Scholar]
- Rao S. S., Peters S. O., Crittenden R. B., Stewart F. M., Ramshaw H. S., Quesenberry P. J. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997 Feb;25(2):114–121. [PubMed] [Google Scholar]
- Stewart F. M., Crittenden R. B., Lowry P. A., Pearson-White S., Quesenberry P. J. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood. 1993 May 15;81(10):2566–2571. [PubMed] [Google Scholar]